Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery

Jensen, Lone Susanne; Kissmeyer-Nielsen, Peter; Wolff, Birgit; Qvist, Niels

doi:10.1016/s0140-6736(96)06168-5

Cited by 401 publications

(363 citation statements)

References 23 publications

Supporting

Mentioning

345

Contrasting

Unclassified

Order By: Relevance

“…33 Surgical patients receiving allogeneic transfusions develop impaired cellular immunity [34][35][36][37][38] associated with increases in postoperative bacterial infections, [39][40][41][42] cancer recurrence, 43,44 multiorgan failure, [45][46][47][48][49][50] and poorer wound healing. [51][52][53] Could ABO nonidentical transfusions cause impaired cellular immune function, infection, and multiorgan failure, but by a different mechanism than that causing hemolysis?…”

Section: Transfusion Studiesmentioning

confidence: 99%

What would Karl Landsteiner do? The ABO blood group and stem cell transplantation

Heal

Liesveld

Phillips

et al. 2005

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:ABO blood group antigens, of great importance in transplantation and transfusion, are present on virtually all cells, as well as in soluble form in plasma and body fluids. Naturally occurring plasma IgM and IgG antibodies against these antigens are ubiquitous. Nonetheless, the ABO blood group system is widely ignored by many transfusion services, except for purposes of red cell transfusion. We implemented a policy of transfusing only ABO identical platelets and red cells in patients undergoing stem cell transplantation or treatment for hematologic malignancies. Major bleeding episodes have occurred in about 5% of patients undergoing induction therapy for acute leukemia as compared with 15-20% in the literature. Overall survival times appear to be superior to that in historical cohorts. In 2002-2004, treatment-related mortality at 100 days in our Blood and Marrow Transplant Unit was 0.7% for autologous transplants (n ¼ 148), 13% for sibling allogeneic transplants (n ¼ 110), and 24% (n ¼ 62) for matched unrelated allogeneic transplants, suggesting that our approach is safe. We speculate that more rigorous efforts on the part of transfusion services to provide ABO identical blood components, and to remove incompatible supernatant plasma, when necessary, might yield reduced morbidity and mortality in patients undergoing stem cell transplantation. Bone Marrow Transplantation (2005) 36, 747-755.

show abstract

Section: Transfusion Studiesmentioning

confidence: 99%

What would Karl Landsteiner do? The ABO blood group and stem cell transplantation

Heal

Liesveld

Phillips

et al. 2005

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Jensen et al further elucidated the effects of transfusion of leukocytedepleted blood and post-operative infection in colorectal surgery, supporting the hypothesis that allogenic leukocytes are partially responsible for transfusioninduced immunosuppression causing impaired immunity. 15 Blood transfusion was found to be an independently associated risk factor for organ/space infection in a previous study. 16 Avoidance of allogenic blood transfusion during elective colorectal surgery is thus recommended.…”

Section: Discussionmentioning

confidence: 84%

Surgical site infection after colorectal cancer surgery in Maiduguri, north-eastern Nigeria

2016

View full text Add to dashboard Cite

“…Randomized controlled trials in cardiac surgery patients have shown that transfusion of leukoreduced allogeneic blood improves short-term 20,21 and in-hospital 22 mortality and infection rates 22 when compared with transfusion of a non-leukoreduced product. Similarly, decreased infection rates were seen in colorectal surgery patients 23 and in a meta-analysis of mixed surgical patients 24 following transfusion of leukoreduced blood. The effectiveness of universal prestorage LR programs is controversial and continues to be debated.…”

Section: Perioperative Transfusion Of Allogeneic Blood Productsmentioning

confidence: 77%

Should intraoperative cell-salvaged blood be used in patients with suspected or known malignancy?

Trudeau

Waters

Chipperfield

2012

Can J Anesth/J Can Anesth

View full text Add to dashboard Cite

Should intraoperative cell-salvaged blood be used in patients with suspected or known malignancy? Les cellules sanguines épargnées en peropératoire doivent-elles être réutilisées chez des patients ayant des processus malins connus ou suspectés? Abstract Purpose Intraoperative cell salvage (ICS) is used as an alternative to allogeneic blood transfusion in an attempt to avoid or minimize the risks associated with allogeneic blood. Intraoperative cell salvage is generally avoided in surgeries where malignancy is confirmed or suspected due to concern for potential metastasis or cancer recurrence. The application of post-processing methods for ICS is hypothesized to eliminate this potential risk. The purpose of this narrative review is to examine the in vitro experimental evidence as it pertains to the removal of tumour cells from ICS blood and to review the clinical studies where ICS blood has been used in patients with malignancy. Source A search of the English literature for relevant articles published from 1973 to 2012 was undertaken using

show abstract

Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery

Cited by 401 publications

References 23 publications

What would Karl Landsteiner do? The ABO blood group and stem cell transplantation

What would Karl Landsteiner do? The ABO blood group and stem cell transplantation

Surgical site infection after colorectal cancer surgery in Maiduguri, north-eastern Nigeria

Should intraoperative cell-salvaged blood be used in patients with suspected or known malignancy?

Contact Info

Product

Resources

About